Sectors & Industries HealthcareDrug Manufacturers - General
Best General Drug Manufacturer Stocks to Buy Now (2025)
Top general drug manufacturer stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best general drug manufacturer stocks to buy now. Learn More.

Industry: Drug Manufacturers - Gene...

Zen Rating Price Value Growth Financials Momentum Sentiment Forecast Dividends Due Diligence

General Drug Manufacturers is Zen Rated A and is the 1st ranked industry out of 145 stock market industries

Ticker	Company	Exchange	Industry	Market Cap	Price	1d %	EBITDA	P/E	D/E	Country
GRFS	GRIFOLS SA	NASDAQ	Drug Manufacturers - General	$6.62B	$9.63	-2.53%	$1.71B	37.62x	2.18	United States
GSK	GSK PLC	NYSE	Drug Manufacturers - General	$81.87B	$40.30	-1.30%	$7.47B	17.75x	3.04	United Kingdom
LLY	ELI LILLY & CO	NYSE	Drug Manufacturers - General	$708.13B	$748.19	-0.95%	$18.75B	48.74x	4.52	United States
BIIB	BIOGEN INC	NASDAQ	Drug Manufacturers - General	$21.01B	$143.32	-1.06%	$2.61B	13.68x	0.61	United States
SNY	SANOFI	NASDAQ	Drug Manufacturers - General	$117.77B	$46.62	-0.87%	$18.05B	10.74x	0.78	France
AMRN	AMARIN CORP PLC	NASDAQ	Drug Manufacturers - General	$308.79M	$14.93	-0.53%	-$94.40M	-2.99x	0.44	Ireland
BMY	BRISTOL MYERS SQUIBB CO	NYSE	Drug Manufacturers - General	$94.34B	$46.35	0.32%	$13.07B	18.61x	4.43	United States
NVS	NOVARTIS AG	NYSE	Drug Manufacturers - General	$238.72B	$123.31	-0.65%	$27.72B	17.85x	1.49	Switzerland
AZN	ASTRAZENECA PLC	NASDAQ	Drug Manufacturers - General	$241.96B	$78.05	-1.90%	$18.51B	29.18x	1.51	United Kingdom
GILD	GILEAD SCIENCES INC	NASDAQ	Drug Manufacturers - General	$139.64B	$112.54	-1.75%	$10.97B	22.29x	1.84	United States
JNJ	JOHNSON & JOHNSON	NYSE	Drug Manufacturers - General	$427.24B	$177.40	-0.37%	$35.65B	18.85x	1.46	United States
PFE	PFIZER INC	NYSE	Drug Manufacturers - General	$136.28B	$23.97	0.42%	$17.31B	12.68x	1.32	United States
ABBV	ABBVIE INC	NYSE	Drug Manufacturers - General	$384.42B	$217.61	-0.33%	$13.80B	103.13x	-750.38	United States
SCLX	SCILEX HOLDING CO	NASDAQ	Drug Manufacturers - General	$178.76M	$25.70	-2.21%	-$68.46M	-2.40x	-1.34	United States
MRK	MERCK & CO INC	NYSE	Drug Manufacturers - General	$202.37B	$81.02	-2.16%	$25.03B	12.46x	1.40	United States
AMGN	AMGEN INC	NASDAQ	Drug Manufacturers - General	$147.73B	$274.40	-0.72%	$15.89B	22.27x	10.83	United States
OGN	ORGANON & CO	NYSE	Drug Manufacturers - General	$2.70B	$10.40	-2.35%	$1.50B	3.84x	17.42	United States
NSRX	NASUS PHARMA LTD	NYSEMKT	Drug Manufacturers - General	N/A	$8.07	-0.86%	-$1.50M	-36.68x	-1.22	Israel
MIRA	MIRA PHARMACEUTICALS INC	NASDAQ	Drug Manufacturers - General	$26.32M	$1.38	-4.83%	-$7.84M	-2.82x	0.52	United States

General Drug Manufacturer Stocks FAQ

What are the best general drug manufacturer stocks to buy right now in Sep 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best general drug manufacturer stocks to buy right now are:

1. Grifols Sa (NASDAQ:GRFS)

Grifols Sa (NASDAQ:GRFS) is the #1 top general drug manufacturer stock out of 19 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Grifols Sa (NASDAQ:GRFS) is: Value: A, Growth: B, Momentum: C, Sentiment: B, Safety: B, Financials: C, and AI: B.

Grifols Sa (NASDAQ:GRFS) has a Due Diligence Score of 33, which is -8 points lower than the general drug manufacturer industry average of 41. Although this number is below the industry average, our proven quant model rates GRFS as a "A".

GRFS passed 13 out of 38 due diligence checks and has average fundamentals. Grifols Sa has seen its stock return 4.22% over the past year, overperforming other general drug manufacturer stocks by 17 percentage points.

Grifols Sa has an average 1 year price target of $10.30, an upside of 6.96% from Grifols Sa's current stock price of $9.63.

Grifols Sa stock has a consensus Hold recommendation according to Wall Street analysts. Of the 1 analyst covering Grifols Sa, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Gsk (NYSE:GSK)

Gsk (NYSE:GSK) is the #2 top general drug manufacturer stock out of 19 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Gsk (NYSE:GSK) is: Value: B, Growth: B, Momentum: C, Sentiment: B, Safety: B, Financials: B, and AI: C.

Gsk (NYSE:GSK) has a Due Diligence Score of 51, which is 10 points higher than the general drug manufacturer industry average of 41.

GSK passed 19 out of 38 due diligence checks and has strong fundamentals. Gsk has seen its stock lose -7.46% over the past year, overperforming other general drug manufacturer stocks by 5 percentage points.

3. Eli Lilly & Co (NYSE:LLY)

Eli Lilly & Co (NYSE:LLY) is the #3 top general drug manufacturer stock out of 19 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Eli Lilly & Co (NYSE:LLY) is: Value: B, Growth: B, Momentum: C, Sentiment: A, Safety: C, Financials: B, and AI: C.

Eli Lilly & Co (NYSE:LLY) has a Due Diligence Score of 65, which is 24 points higher than the general drug manufacturer industry average of 41.

LLY passed 26 out of 38 due diligence checks and has strong fundamentals. Eli Lilly & Co has seen its stock lose -18.99% over the past year, underperforming other general drug manufacturer stocks by -7 percentage points.

Eli Lilly & Co has an average 1 year price target of $914.75, an upside of 22.26% from Eli Lilly & Co's current stock price of $748.19.

Eli Lilly & Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 8 analysts covering Eli Lilly & Co, 87.5% have issued a Strong Buy rating, 0% have issued a Buy, 12.5% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the general drug manufacturer stocks with highest dividends?

Out of 13 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

1. Organon & Co (NYSE:OGN)

Organon & Co (NYSE:OGN) has an annual dividend yield of 5.77%, which is 3 percentage points higher than the general drug manufacturer industry average of 3.04%. Organon & Co's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Organon & Co's dividend has not shown consistent growth over the last 10 years.

Organon & Co's dividend payout ratio of 31.7% indicates that its high dividend yield is sustainable for the long-term.

2. Sanofi (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) has an annual dividend yield of 4.75%, which is 2 percentage points higher than the general drug manufacturer industry average of 3.04%. Sanofi's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Sanofi's dividend has shown consistent growth over the last 10 years.

Sanofi's dividend payout ratio of 51% indicates that its high dividend yield is sustainable for the long-term.

3. Gsk (NYSE:GSK)

Gsk (NYSE:GSK) has an annual dividend yield of 4.08%, which is 1 percentage points higher than the general drug manufacturer industry average of 3.04%. Gsk's dividend payout is not stable, having dropped more than 10% nine times in the last 10 years. Gsk's dividend has not shown consistent growth over the last 10 years.

Gsk's dividend payout ratio of 70.7% indicates that its high dividend yield is sustainable for the long-term.

Why are general drug manufacturer stocks down?

General drug manufacturer stocks were down -0.92% in the last day, and down -0.01% over the last week. Mira Pharmaceuticals was the among the top losers in the drug manufacturers - general industry, dropping -4.83% yesterday.

MIRA stock has given up its prior gain. MIRA Pharmaceuticals shares were trading higher after the company announced results from a proof-of-concept validation study evaluating Ketamir-2 in an animal model of post-traumatic stress disorder

What are the most undervalued general drug manufacturer stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued general drug manufacturer stocks right now are:

1. Organon & Co (NYSE:OGN)

Organon & Co (NYSE:OGN) is the most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Organon & Co has a valuation score of 71, which is 32 points higher than the general drug manufacturer industry average of 39. It passed 5 out of 7 valuation due diligence checks.

Organon & Co's stock has dropped -50.19% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -38 percentage points.

2. Merck & Co (NYSE:MRK)

Merck & Co (NYSE:MRK) is the second most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Merck & Co has a valuation score of 57, which is 18 points higher than the general drug manufacturer industry average of 39. It passed 4 out of 7 valuation due diligence checks.

Merck & Co's stock has dropped -31.32% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -19 percentage points.

3. Biogen (NASDAQ:BIIB)

Biogen (NASDAQ:BIIB) is the third most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Biogen has a valuation score of 86, which is 47 points higher than the general drug manufacturer industry average of 39. It passed 6 out of 7 valuation due diligence checks.

Biogen's stock has dropped -28.19% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -16 percentage points.

Are general drug manufacturer stocks a good buy now?

40% of general drug manufacturer stocks rated by analysts are a buy right now. On average, analysts expect general drug manufacturer stocks to rise by 43.17% over the next year.

21.05% of general drug manufacturer stocks have a Zen Rating of A (Strong Buy), 36.84% of general drug manufacturer stocks are rated B (Buy), 36.84% are rated C (Hold), 5.26% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the drug manufacturers - general industry?

The average P/E ratio of the drug manufacturers - general industry is 37x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.

General Drug Manufacturer Stocks FAQ

1. Grifols Sa (NASDAQ:GRFS)

2. Gsk (NYSE:GSK)

3. Eli Lilly & Co (NYSE:LLY)

1. Organon & Co (NYSE:OGN)

2. Sanofi (NASDAQ:SNY)

3. Gsk (NYSE:GSK)

1. Organon & Co (NYSE:OGN)

2. Merck & Co (NYSE:MRK)

3. Biogen (NASDAQ:BIIB)

Company

Stock Tools

Stock Ideas